Asthma medication use in pregnancy and fetal growth

The treatment of asthma with systemic corticosteroids resulted in a deficit of about 200 g in birth weight compared with controls and exclusive β2-agonist users and no increased incidence of SGA. These results suggest that asthma management with β2-agonists and/or inhaled corticosteroids during pregnancy does not impair fetal growth, whereas systemic corticosteroids have a minimal effect which should be weighed against the necessity to control severe asthma.